Full text is available at the source.
Engineering adoptive cell therapy for solid tumors
Improving immune cell therapy to treat solid tumors
AI simplified
Abstract
Adaptive cell therapy (ACT) may enhance personalized cancer treatment for solid tumors by utilizing engineered immune cells.
- ACT has demonstrated significant success in treating blood cancers but faces challenges in solid tumors.
- Challenges include limited immune cell infiltration, varying tumor cell markers, and an environment that suppresses immune responses.
- Strategies to improve ACT's effectiveness focus on engineered T cells, including CAR-T, TCR-T, and tumor-infiltrating lymphocytes (TILs).
- Recent advancements aim to target tumors better, resist signals that suppress immune activity, and prevent tumor cells from evading detection.
- Gene-editing tools like CRISPR/Cas9 are being explored to create next-generation immune cells with improved capabilities and safety.
AI simplified